Takeda appoints new CMSO and CCO

To strengthen the Japanese firm as it integrates Nycomed

Japanese drugmaker Takeda has established the new positions of chief medical and scientific officer (CMSO) and chief commercial officer (CCO), to strengthen the company’s governance and business operations as it fully integrates the Nycomed organisation and becomes a global pharmaceutical company.

Dr Tadataka Yamada, a medical doctor and scientist with vast global experience in pharmaceutical r&d and a member of the Takeda board, has been appointed CMSO. The position of chief scientific officer has been abolished.

The new CCO is Dr Frank Morich, also a board member, who will drive sales strategies in the US and EU markets, and also in the fast growing emerging markets. The positions of International Operations (Americas/Europe) and International Operations (North Asia) have been abolished and replaced by the CCO, who will preside over Takeda’s global sales structure (with the exclusion of Millennium and Japanese domestic sales), including most former Nycomed countries and functions.

You may also like